Lewis Asset Management LLC Has $425,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Lewis Asset Management LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 9.7% in the fourth quarter, HoldingsChannel reports. The firm owned 4,942 shares of the company’s stock after selling 530 shares during the period. Lewis Asset Management LLC’s holdings in Novo Nordisk A/S were worth $425,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Novare Capital Management LLC lifted its holdings in Novo Nordisk A/S by 3.2% during the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after buying an additional 85 shares in the last quarter. Rosenberg Matthew Hamilton raised its position in shares of Novo Nordisk A/S by 2.5% during the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock worth $454,000 after acquiring an additional 94 shares during the last quarter. Burns J W & Co. Inc. NY lifted its stake in shares of Novo Nordisk A/S by 1.9% during the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after acquiring an additional 100 shares during the period. Spinnaker Trust boosted its holdings in Novo Nordisk A/S by 1.1% in the third quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after acquiring an additional 100 shares during the last quarter. Finally, Marco Investment Management LLC increased its position in Novo Nordisk A/S by 1.5% in the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after purchasing an additional 100 shares during the period. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 1.3 %

NVO opened at $84.05 on Thursday. The firm’s fifty day moving average is $94.75 and its two-hundred day moving average is $114.02. The firm has a market cap of $377.17 billion, a PE ratio of 27.20, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.